Clinical Development Programs
The Astellas partnership includes a treatment for hypercholesterolemia (evolocumab), a treatment for osteoporosis (romosozumab) and a treatment for oncology (blinatumomab).
Co-developed Pipeline Medicines between Amgen Astellas BioPharma and Astellas Pharma
General Name
(Development Code) |
Lead Indication |
Mode of Action |
Development Stage |
|
Overseas |
Japan |
Evolocumab (AMG 145) |
Hypercholesterolemia |
Anti-PCSK-9 mAb |
Launch |
Launch |
Romosozumab (AMG 785)1 |
Osteoporosis |
Anti-Sclerostin mAb |
Filed |
Launch |
Blinatumomab (AMG 103) |
Acute Lymphoblastic
Leukemia (ALL) |
Anti-CD19 BiTE® |
Launch |
Launch
|
Pipeline Medicines by Amgen Astellas BioPharma
General Name
(Development Code) |
Lead Indication |
Mode of Action |
Development Stage |
|
Overseas |
Japan |
Talimogene Laherparepvec(AMG 678) |
Malignant Melanoma |
Oncolytic Virus |
Launch |
Phase 1 |
Erenumab(AMG 334) |
Migraine prevention |
Anti-CGRP Receptor
mAb |
Launch |
Phase 3
|
Omecamtiv Mecarbil (AMG 423)2 |
Chronic heart failure |
Cardiac myosin
activator |
Phase 3 |
Phase 3 |